RESEARCH ARTICLE

Two Arginine Residues of *Streptococcus gordonii* Sialic Acid-Binding Adhesin Hsa Are Essential for Interaction to Host Cell Receptors

Yumiko Urano-Tashiro1*, Yukihiro Takahashi1, Riyo Oguchi2, Kiyoshi Konishi1

1 Department of Microbiology, Nippon Dental University School of Life Dentistry at Tokyo, Fujimi, Chiyoda-ku, Tokyo, Japan, 2 Department of Pediatric Dentistry, Nippon Dental University School of Life Dentistry at Tokyo, Fujimi, Chiyoda-ku, Tokyo, Japan

* yumiurano@tky.ndu.ac.jp

Abstract

Hsa is a large, serine-rich protein of *Streptococcus gordonii* DL1 that mediates binding to α2-3-linked sialic acid termini of glycoproteins, including platelet glycoprotein Ibα, and erythrocyte membrane protein glycoporhin A, and band 3. The binding of Hsa to platelet glycoprotein Ibα contributes to the pathogenesis of infective endocarditis. This interaction appears to be mediated by a second non-repetitive region (NR2) of Hsa. However, the molecular details of the interaction between the Hsa NR2 region and these glycoproteins are not well understood. In the present study, we identified the amino acid residues of the Hsa NR2 region that are involved in sialic acid recognition. To identify the sialic acid-binding site of Hsa NR2 region, we prepared various mutants of Hsa NR2 fused with glutathione transferase. Fusion proteins harboring Arg340 to Asn (R340N) or Arg365 to Asn (R365N) substitutions in the NR2 domain exhibited significantly reduced binding to human erythrocytes and platelets. A sugar-binding assay showed that these mutant proteins abolished binding to α2-3-linked sialic acid. Furthermore, we established *S. gordonii* DL1 derivatives that encoded the corresponding Hsa mutant protein. In whole-cell assays, these mutant strains showed significant reductions in hemagglutination, in platelet aggregation, and in adhesion to human leukocytes. These results indicate that the Arg340 and Arg365 residues of Hsa play an important role in the binding of Hsa to α2-3-linked sialic acid-containing glycoproteins.

Introduction

The oral streptococci, including *Streptococcus gordonii*, is associated with primary dental plaque formation [1]. *S. gordonii* and related species of the viridans group of streptococci colonize damaged heart valves and are recognized as etiological bacterial agents of infective endocarditis (IE) [2–4].
S. gordonii adhere to saliva-coated hydroxyapatite, an experimental model of the tooth surface, and bind to host cells such as erythrocytes, platelets, polymorphonuclear leukocytes (PMNs), macrophages, and monocytes [5–10]. A common mechanism for these interactions is the recognition of surface-associated host sialoglycoconjugates. The binding of S. gordonii to human platelets on the surface of damaged cardiac valves is an important initiation step in the pathogenesis of IE [11]. Recent studies have reported the adhesins of streptococci that bind human platelets including serine-rich surface proteins designated Hsa, GspB, SrpA, and Srr1, an antigen I/II (Agl/II) family polypeptides SspA and SspB, and surface proteins PdaA, PblA, and PblB [12–18]. Attachment of S. gordonii DL1 to host cells is facilitated predominantly by Hsa, which mediates bacterial binding to the sialic acid moiety of receptors on host cell membrane.

S. gordonii DL1 Hsa consists of an N-terminal nonrepetitive region (NR1), a serine-rich region (SR1), another nonrepetitive region (NR2), another serine-rich region (SR2), and a C-terminal cell wall-anchoring region [19]. Hsa binds to the α2-3-linked sialic acid-containing glycoproteins, including salivary mucin MG2, platelet glycoprotein Ibα (GPIbα), and leukosialin (CD43), the major surface protein of human PMNs [5, 12, 20, 21]. The NR2 region of Hsa is involved in the binding interaction between α2-3-linked sialic acid and Hsa [7]. In previous work, we identified glycophorin A (GPA) and band 3 as erythrocyte receptors for Hsa [8]. Moreover, CD11b and CD50 have been identified as leukocyte receptors for Hsa [9]. Two Hsa homologues, GspB of S. gordonii strain M99 and SrpA of Streptococcus sanguinis strain SK36, bind human platelets through sialic acid-dependent interactions with GPIbα [14, 22].

Hsa, GspB, and SrpA are all α2-3-linked sialic acid-binding proteins, but the three homologues show distinct specificities. The NR2 of Hsa and the binding region of SrpA each can bind both 3′-sialyllactose [Neu5Acα2-3Galβ1-4Glc] and sialyl-T antigen [Neu5Acα2-3Galβ1-3GalNAc], whereas the binding region of GspB binds only sialyl-T antigen [13, 23]. The binding region of GspB contains the V-set Ig fold adopted by eukaryotic Siglec (sialic acid binding immunoglobulin-like lectins)-like domain. Moreover, Arg484 of GspB is important for binding to α2–3 sialyl-glycoproteins [24]. Hsa contains a Siglec-like domain in NR2 [24]. However, the molecular details of the interaction between Hsa NR2 region and the target sialylated carbohydrates are not well understood. In the present study, we have identified two amino acid residues of Hsa that are involved in sialic acid interaction. Our results show that Arg340 and Arg365 of Hsa play an important role in the binding of S. gordonii DL1 to human cell surface glycoproteins.

Materials and Methods

Ethics statement

All research involving human participants have been approved by our Instructional Review Board. Healthy donor was informed and gave his written consent for using the collected samples in a scientific study. Collection and use of blood samples in this study was approved by the Research Ethics Committee of Nippon Dental University (NDU-T2012-33).

Bacterial strains and growth conditions

The S. gordonii strains used in this study were DL1 (Challis strain; wild type) and its derivative CM100 (DL1 @hsa cat) [6, 7]. Streptococci were cultured overnight at 37°C in brain heart infusion broth (Becton Dickinson, Franklin Lakes, NJ). The medium was supplemented (as needed) with 200 μg/ml of spectinomycin dihydrochloride or 8 μg/ml of chloramphenicol (Sigma-Aldrich, St. Louis, MO). Escherichia coli BL21 harboring the plasmids with ampicillin resistance was grown in Luria-Bertani broth containing 100 μg/ml ampicillin (Sigma-Aldrich).
Construction and purification of glutathione S-transferase-HsaNR2 fusion proteins.

Glutathione S-transferase (GST) -HsaNR2 fusion protein was constructed, and the expressed protein was purified, as described previously [8]. Site-directed mutagenesis was performed using the QuickChange Site-Directed Mutagenesis kit (Strategene, La Jolla, CA) and the following primer pairs: R308Q (Arg308 to Gln308) (5’-primer: 5’-GAG AAT CTT GGT CAG CCT GGT AAT GC-3’, 3’-primer: 5’-GCA TTA CCA GGC TGA CCA AGA TTC TC-3’), R319N (5’-primer: 5’-CCT CTC AAC ACT AGA ATA TTT GGT G-3’, 3’-primer: 5’-CAC CAA ATA TTC TAG TGT TGA G-3’), R321N (5’-primer: 5’-CCT CTC CGG ACT AAC ATA TTG GGT G-3’, 3’-primer: 5’-CAC CAA ATA TGT TAG TCC GGA GAG G-3’), R340N (5’-primer: 5’-CTT ATT ATA CTA ATT ATA TAG TTG GAG G-3’, 3’-primer: 5’-CGC AAC TAT ATA ATT AGT AGT AG-3’), R360N (5’-primer: 5’-CCT CTC CGG ACT AAC ATA TTG GGT G-3’, 3’-primer: 5’-CTA GTC CAT TAT TAG CAT TAT CC-3’), and R365N (5’-primer: 5’-GGA TAA TGC TAA TAA CAA TGG ACT AG-3’, 3’-primer: 5’-CTA GTC CAT TAT TAG CAT TAT CC-3’). The plasmids containing genes encoding HsaNR2 with R308Q, R319N, R321N, R340N, R360N, or R365N mutations were designated as pGEX-HsaNR2R308Q, pGEX-HsaNR2R319N, pGEX-HsaNR2R321N, pGEX-HsaNR2R340N, pGEX-HsaNR2R360N, and pGEX-HsaNR2R365N, respectively.

Hemagglutination assay

The hemagglutination (HA) assay was performed as previously described [6] by mixing 25 μl of serial dilutions of bacteria (starting at 2 × 10⁹ cells/ml) or GST-fusion protein (starting at 2 mg/ml) with equal volumes of 1% human type-O erythrocytes in the individual wells of 96-well round-bottom microtiter plates. The plates were incubated at 4°C overnight. Positive results were scored as agglutinated cell sheets compared to non-agglutinated cell bottoms. Images of hemagglutination were taken with a digital camera (EOS X3, Canon, Japan).

Platelet aggregation assay

The platelet bacterial adhesion assay was performed as previously described [7] using platelets obtained by centrifugation of platelet-rich plasma from citrated human type O blood. Specifically, aliquots (50 μl) of bacteria (at 2 × 10⁹ cells/ml) or GST-fusion protein (at 2 mg/ml) were mixed with equal volumes of washed platelets (at 5 × 10⁸ cells/ml) in the individual wells of 96-well microtiter plates. The plates were incubated for 30 min at room temperature (RT). Supernatants containing unaggregated platelets were harvested following low-speed centrifugation (35 × g) and were diluted 1:2 with Tris-buffered saline (TBS; 20 mM Tris-HCl, pH 7.8, 150 mM NaCl, 10 mM ethylenediaminetetraacetic acid) prior to measurement of absorbance at 620 nm (A₆₂₀). Differences in platelet aggregation were statistically analyzed using unpaired t-test. P values < 0.05 were considered statistically significant.

Sugar-binding assay

GST-HsaNR2 fusion proteins were diluted to 500 nM into phosphate-buffered saline (PBS) and then subjected to serial two-fold dilutions in PBS. 50 μl of each dilution were transferred to the individual wells of a 96-well microtiter plate. After adsorption by overnight incubation at RT, wells were rinsed with PBS and blocked with PBS containing 1% blocking reagent (Roche, Mannheim, Germany) for 1 h at RT. The wells were incubated for 90 min at RT with 50 μl of
biotinylated 3'-sialyllactose or sialyl-T antigen (each at 500 ng/ml; GlycoTech, Gaithersburg, MD), and unbound biotinylated 3'-sialyllactose and sialyl-T antigen was removed by rinsing three times with PBS. 50 μl of avidin-D-horseradish peroxidase (0.1 μg/ml in PBS) (Vector, Burlingame, CA) was added to each well; plates were incubated for 1 h at RT, and the unbound peroxidase was removed by rinsing three times with PBS. An aliquot (100 μl) of a solution of o-phenylenediamine (OPD; 1 mg/ml in citrate-phosphate buffer) was added to each well; following incubation for several minutes at RT, 50 μl of 2 M H2SO4 was added to each well to stop the reaction. The contents of the wells were mixed by gently vortexing the plate, and A490 was measured. Data are provided as the mean ± standard deviation, with n = 6.

**Generation of hsa NR2 point mutant constructs**

Each hsa NR2 point mutant plasmid was prepared from plasmid pAS8743, which lacks a BglII site within the multiple cloning site of pAS8741 [7]. HsaNR2 mutants substituting Arg340 and Arg365 for Asn were created by PCR using the QuickChange Site-Directed Mutagenesis kit and the primers described above. pIRH206, a deletion mutant derivative of pIRH801 harboring a 1.9-kb fragment [19], was used as the template for these PCR reactions. pAS8743R340N was constructed by the insertion of the HindIII-BglII fragment from pIRH206R340N into the HindIII-BglII site of pAS8743. pAS8743R365N was constructed by the insertion of the HindII-BglII fragment from pIRH206R365N into the HindIII-BglII site of pAS8743. These plasmids were transformed as previously described [25] into S. gordonii CM100. The transformants harboring the original and mutated plasmids (pAS8743WT, pAS8743R340N, and pAS8743R365N) were designated CM100 (WT), CM100 (R340N), and CM100 (R365N), respectively. Expression of mutant Hsa proteins on the bacterial cell surface was verified by western blotting as described below.

**Analysis of cell wall proteins**

Bacteria were harvested from cultures in the logarithmic phase of growth. 1 × 1010 of bacterial cells were digested with mutanolysin (Sigma-Aldrich) in the presence of raffinose (26% wt/vol), as described previously [7]. Samples were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 3 to 8% gradient gel (Life Technologies, Carlsbad, CA), and electrophoretically transferred to PVDF membranes (Bio-Rad, Hercules, CA) for western blotting with anti-Hsa (1:1000 dilution) or anti-DL1 (1:10,000 dilution) antibody as previously described [7].

**Attachment of bacteria to human leukocytes**

Human leukocytes were isolated from peripheral blood collected from healthy donors. Erythrocytes were removed by dextran segmentation and hypotonic lysis. Leukocytes were washed three times and resuspended in RPMI-1640 supplemented with 1% bovine serum albumin (BSA), 0.2% HEPES, and 0.15 mM CaCl2. Leukocyte preparations (1×106 cells/ml) were challenged with bacteria (1×108 cells/ml) for 2 h at 37°C. Cells were washed twice with 1 × PBS containing 1% BSA and stained by the Wright-Giemsa method using Diff-Quick (sysmex, Kobe, Japan). Bacteria binding to leukocytes were quantitatively evaluated by counting the bacterial cell number on the surface of 30 randomly selected neutrophils, eosinophils, monocytes, or lymphocytes. The glass slides were imaged by an upright microscope (LABOPHOT-2, Nicon, Japan). Differences between means were compared for statistical significance by the unpaired t-test using P < 0.05 as the threshold for significance.
Results

The middle of the Hsa NR2 region is required for interaction with erythrocytes

To define the region of Hsa required for the interaction with sialic acid, we prepared three truncation mutants of HsaN2R2 fused with GST (Fig 1A). We previously reported that Hsa bound to erythrocyte membrane-associated protein in a α2-3-linked sialic acid-dependent manner [8]. In the present work, we used the HA assay to test the ability of GST-fused protein to bind α2-3-linked sialic acid. Erythrocytes were pretreated with each of several GST-fused proteins, followed by the bacterial HA assay. Bacteria-mediated HA was inhibited only by GST-HsaN2R2-3-2 (Fig 1B left panel), a construct that includes Hsa residues corresponding to amino acids 298–377 of the full-length protein. Other GST-fused proteins had no effect on bacteria-mediated HA. In the control experiment, HA was observed when erythrocytes were incubated with GST-HsaN2R2 (Fig 1B right panel) alone, as described previously [8]. This result indicates that the 298–377 region of Hsa binds to α2-3-linked sialic acid-containing erythrocyte surface glycoproteins.

Hemagglutination activity is abolished by conservative substitution of a single Arg residue

To identify the amino acid residue(s) of the Hsa 298–377 region involved in α2-3-linked sialic acid recognition, we constructed six mutants of GST-HsaN2R2, each of which contained a single substitution at an arginine residue (R308Q, R319N, R321N, R340N, R360N, and R365N), and repeated the HA assay (Fig 2). As expected, HA was observed in a control experiment, when erythrocytes were incubated with GST-HsaN2R2WT. HA activity was abolished completely when erythrocytes were incubated with GST-HsaN2R340N or GST-HsaN2R365N. Other mutant GST-HsaN2R proteins (with R308Q, R319N, R321N, or R360N lesions) had HA activities similar to that observed with GST-HsaN2R2WT. These results show that Arg340 and Arg365 play a role in the interaction between Hsa and α2-3-linked sialic acid-containing glycoproteins.

Arg 340 and Arg365 are essential for Hsa adhesion to human platelets

We selected the R340N and R365N mutations for more detailed evaluation. S. gordonii DL1 has not only HA activity but also platelet aggregation activity. Therefore, we analyzed the involvement of Arg340 and Arg365 in the attachment of Hsa to platelets. Washed human platelets were mixed with GST- HsaN2R2 mutant proteins for 30 min at room temperature (Fig 3). Almost full aggregation was observed when GST-HsaN2R2WT was mixed with platelets (99.4 ± 0.28%). In contrast, GST-HsaN2R2R340N, GST-HsaN2R2R365N, and GST exhibited reduced interactions with platelets in the same assay (3.70 ± 5.11%, 7.36 ± 9.66%, and 8.90 ± 12.3%, respectively). These results demonstrate that Arg340 and Arg365 play a role in the binding of Hsa to platelets.

Arg340 and Arg365 are involved in binding to α2-3-linked sialylated carbohydrates

Hsa can bind not only to 3’-sialyllactose but also to sialyl-T antigen [13]. Therefore, we examined the sialic acid-binding specificity of GST-HsaN2R2 mutant proteins using ELISA assay. GST-HsaN2R2WT bound both 3’-sialyllactose and sialyl-T antigen, whereas GST-HsaN2R2R340N and GST-HsaN2R2R365N completely eliminated the binding of any trisaccharide structures (Fig 4). Binding activity of either of the two mutant proteins was
comparable to that of GST alone, a negative control. These results indicate that Arg340 and Arg365 are necessary for sialic acid binding activity of Hsa.

Arg340 and Arg365 are required for the sialic acid binding activity of S. gordonii DL1

To confirm further that Arg340 and Arg365 of Hsa are required for the binding of α2-3-linked sialic acid-containing glycoproteins, we established hasa mutants of S. gordonii DL1 and assayed the resulting strains in whole-cell assays. Plasmids harboring mutated hasa were prepared from pAS8743WT and transformed into S. gordonii CM100, an hasa-deleted strain. The transformants harboring these plasmids (pAS8743WT, pAS8743R340N, and pAS8743R365N) were designated CM100 (WT), CM100 (R340N), and CM100 (R365N), respectively. The amount of Hsa on the bacterial cell surface was analyzed by western blotting with anti-Hsa antibody. None of the point mutations affected surface expression of Hsa. Western blot profile with anti-DL1 panel showed that the proteins except Hsa were expressed at equivalent levels in all the
mutations and wild-type cells (Fig 5A). We next analyzed the HA activity of *S. gordonii* CM100-derived strains. *S. gordonii* DL1 and CM100(WT) had HA activity, while CM100 (R340N), CM100 (R365N), and CM100 (with no plasmid) lacked HA activity (Fig 5B). The platelet aggregation assay revealed that a large number of platelets were aggregated with *S. gordonii* DL1 (85.4 ± 2.10%) and CM100 (WT) (42.3 ± 4.78%). In contrast, platelet aggregation was decreased with CM100 (R340N) (16.9 ± 5.42%), CM100 (R365N) (19.3 ± 5.98%), and CM100 (14.5 ± 3.08%) (Fig 5C). These results show the importance of the Arg340 and Arg365 residues for the binding of *S. gordonii* DL1 to erythrocyte and platelet surface glycoproteins.

![Hemagglutination of human erythrocytes by GST-HsaNR2 mutant proteins.](image1)

Fig 2. Hemagglutination of human erythrocytes by GST-HsaNR2 mutant proteins. 0.3% human erythrocytes were incubated (overnight at 4°C) with serial dilutions of GST-fused HsaNR2 mutant proteins. doi:10.1371/journal.pone.0154098.g002

![Mutation of Arg340 and Arg365 residues abolishes platelet aggregation activity.](image2)

Fig 3. Mutation of Arg340 and Arg365 residues abolishes platelet aggregation activity. Washed human platelets were incubated (for 30 minutes at room temperature) with 0.33 mg/ml of GST, GST-HsaNR2WT, or GST-HsaNR2 proteins harboring R340N or R365N substitutions. Percent aggregation of platelets was determined spectrophotometrically. The mean numbers of percent aggregation and standard deviations were determined by six independent experiments. Statistical differences in the means of obtained values were evaluated by an unpaired t-test (*P < 10^-5*). doi:10.1371/journal.pone.0154098.g003
Adhesion of *S. gordonii* DL1 to human leukocytes is mediated by Arg340 and Arg365 of Hsa

We reported previously that the binding of *S. gordonii* DL1 to monocytes, granulocytes, and macrophages is mediated by Hsa [9]. Therefore we examined the ability of *S. gordonii* CM100 strains to adhere to human peripheral leukocytes, such as neutrophils, eosinophils, monocytes, and lymphocytes. Human leukocytes were incubated for 2 h with *S. gordonii* strains at a ratio of 100 bacterial cells per host cell. Large numbers of bacterial cell adhered to host cells incubated with *S. gordonii* DL1 (Fig 6Aa–6Ad) or CM100 (WT) (Fig 6Ai–6Al). By contrast, when CM100 (Fig 6Ae–6Ah), CM100 (R340N) (Fig 6Am–6Ap), or CM100 (R365N) (Fig 6Aq–6At) were incubated with host cells, low numbers of bacterial cells bound to host cells. All of these differences were statistically significant ($P < 10^{-14}$) (Fig 6B). These results indicate that Arg340 and Arg365 of Hsa play an essential role in bacterium-host cell interaction.
Fig 5. Essential role of Hsa Arg340 and Arg365 in adhesion to erythrocytes and platelets. (A) Expression of wild-type and mutant Hsa proteins on the S. gordonii cell surface. Peptidoglycan-linked proteins were extracted from bacterial cell surface and analyzed by western blotting using anti-Hsa or anti-DL1 antibody. The position of the molecular mass marker is indicated on the left in kilodaltons. (B) Hemagglutination of human erythrocytes by S. gordonii. 0.3% human erythrocytes were incubated (overnight at 4°C) with serial dilutions of S. gordonii DL1 or derivative strains. (C) Platelet aggregation activity of S. gordonii. Washed human platelets were incubated (for 30 minutes at room temperature) with S. gordonii DL1 or derivative strains. Percent aggregation of platelets was determined spectrophotometrically. The mean numbers of percent aggregation and standard deviations were determined by five independent experiments. Statistical differences in the means of obtained values were evaluated by an unpaired t-test (**P < 0.0001).

doi:10.1371/journal.pone.0154098.g005
Fig 6. Attachment of S. gordonii DL1 to human leukocytes. (A) Human leukocytes (5× 10⁵ cells) were incubated with S. gordonii DL1 (a, b, c, and d), CM100 (e, f, g, and h), CM100 (WT) (i, j, k, and l), CM100 (R340N) (m, n, o, and p), or CM100 (R365N) (q, r, s, and t) (5× 10⁷ cells) for 2 h at 37°C. Bacterial binding was determined microscopically using Wright-Giemsa staining. Arrowheads indicate phagosomes that appear to contain intact bacterial cells. Original magnification, × 1000. Scale bar = 10 μm. (B) The means and standard deviations of bacteria cell numbers bound to randomly selected neutrophils, eosinophils, monocytes, or lymphocytes (n = 30) are indicated. Statistical differences in the means of obtained values were evaluated by an unpaired t-test (** P < 10⁻¹⁴).
Discussion

Hsa is a cell surface protein of *S. gordonii* that binds to the α2-3-linked sialic acids contained in glycoproteins. The binding of Hsa to sialic acid is mediated by the NR2 region of Hsa. Some glycoproteins, including GP Ibα, GPA, and band 3, have been identified as receptors for Hsa. However, the molecular details of the interaction between Hsa NR2 region and these glycoproteins are not well understood. To determine the amino acid residues that mediate the interaction between Hsa and sialic acid, we used GST-fused proteins.

The results of our examination demonstrate that Arg340 and Arg365 in the NR2 region are critical for the sialic acid-binding activity of Hsa. Mutation of these amino acid residues abrogated the ability of both purified protein and bacterial cells to interact with host cells.

This study indicated that Hsa can bind a broad range of α2-3-linked sialic acids, including 3’-sialyllactose, sialyl-T antigen, and Neu5Acα2-3Galβ1-4GlcNAc. These results are consistent with the previous study [23]. GST-tagged NR2 domains harboring mutations at either Arg340 or Arg365 exhibited significantly reduced binding to each of the tested sialic acids. Structural prediction using Spanner server ([https://sysimm.ifrec.osaka-u.ac.jp/spanner/](https://sysimm.ifrec.osaka-u.ac.jp/spanner/)) suggests that the middle of the NR2 region of Hsa, including Arg340 and Arg365, forms a pocket. These two Arg are predicted to be positioned on opposite sides of the hypothesized pocket. Thus, the bound sialic acid may be bracketed by Arg340 and Arg365 upon binding by Hsa. In GspB, Arg484 is required for binding to sialyl-T antigen [24]. Amino acid sequence alignment suggests that Arg484 of GspB corresponds to Arg340 of Hsa [13]. Arg365 of Hsa corresponds to Lys509 of GspB. As Lys is a positively charged amino acid, this residue should show affinity for a negatively charged sialic acid. Indeed, we found that a mutant protein in which Arg365 is changed to Lys retains weak sialic acid binding activity (data not shown). This Arg residue is conserved among many Hsa homologues reported in public databases and in sequence data from our laboratory (data not shown). Thus, this Arg is predicted to be critical to the binding of sialic acid by other streptococci.

*S. gordonii* binds to host blood cells such as erythrocytes, platelets, PMNs, and monocytes [5, 7–9, 12]. That binding is attributed to interactions between Hsa and the α2-3-linked sialic acid glycoproteins that are displayed on the host cell surface. In extension of our GST-HsaNR2 studies, we established derivatives of a *S. gordonii* DL1 *hsa* mutant strain that expressed HsaR340N or HsaR365N. Expression of the mutant protein dramatically decreased whole-cell binding of *S. gordonii* to erythrocytes [26] and to leukocytes (e.g., neutrophils, eosinophils, monocytes, and lymphocytes). These results indicate that Arg340 and Arg365 are involved in the interaction between *S. gordonii* and host cell sialoglycoproteins.

The first step in the pathogenesis of IE is the deposition of platelet-fibrin aggregates on injured valves. Bacteria circulating in the blood bind to such nonbacterial thrombotic endocarditic lesions [27]. Platelet aggregation by *S. gordonii* CM derivatives CM100 (R340N) and CM100 (R365N) was significantly reduced. Thus, Arg340 and Arg365 of Hsa are important for binding to platelets. This result suggests that Arg340 and Arg365 of Hsa contribute to the pathogenesis of IE by *S. gordonii* DL1.

IE is a serious septic disease. After the formation of vegetation on the damaged endothelium, microbial shedding by continuous bacteremia and embolization of the vegetation fragment can lead to multiple organ dysfunction syndromes such as ischemic stroke, brain abscess, and mycotic aneurysm [27]. Despite advances in diagnosis, antibacterial therapy, and surgical techniques, the incidence of and mortality from IE has not been reduced over the past 30 years. The incidence of IE is 1.4–12.7 per 100,000 person-years. Without treatment, IE is frequently lethal. One-year mortality is up to 40% [27]. Prevention of IE requires treatment with high-dose antimicrobial agents before invasive surgical techniques such as dental procedures [28].
This treatment is burden to patients. Drugs that interact with the Arg340- and Arg365-containing region of Hsa might find application as new inhibitors of bacterial binding. Our insight thus may facilitate the development of new drugs for the prevention of IE.

**Author Contributions**

Conceived and designed the experiments: YU-T YT KK. Performed the experiments: YU-T YT. Analyzed the data: YU-T YT RO KK. Contributed reagents/materials/analysis tools: YT RO. Wrote the paper: YU-T YT.

**References**

1. Rosan B, Lamont RJ. Dental plaque formation. Microbes Infect 2000; 2: 1599–1607. PMID: 11113379.
2. Baddour LM. Virulence factors among gram-positive bacteria in experimental endocarditis. Infect Immun 1994; 62: 2143–2148. PMID: 8188334.
3. Baddour LM, Christensen GD, Lowrance JH, Simpson WA. Pathogenesis of experimental endocarditis. Rev Infect Dis. 1989; 11: 452–463. PMID: 2665003.
4. Durack DT. Prevention of infective endocarditis. N Engl J Med 1995; 332: 38–44. doi: 10.1056/nejm199501053320107 PMID: 7990863.
5. Ruhl S, Cisar JO, Sandberg AL. Identification of polymorphonuclear leukocyte and HL-60 cell receptors for adhesins of *Streptococcus gordonii* and Actinomyces naeslundii. Infect Immun 2000; 68: 6346–6354. PMID: 11035744.
6. Takahashi Y, Sandberg AL, Ruhl S, Muller J, Cisar JO. A specific cell surface antigen of *Streptococcus gordonii* is associated with bacterial hemagglutination and adhesion to α2-3-linked sialic acid-containing receptors. Infect Immun 1997; 65: 5042–51. PMID: 993797.
7. Takahashi Y, Yajima A, Cisar JO, Konishi K. Functional analysis of the *Streptococcus gordonii* DL1 sialic acid-binding adhesin and its essential role in bacterial binding to platelets. Infect Immun 2004; 72: 3876–3882.
8. Yajima A, Urano-Tashiro Y, Shimazu K, Takashima E, Takahashi Y, Konishi K. Hsa, an adhesin of *Streptococcus gordonii* DL1, binds to α2-3-linked sialic acid on glycoporphin A of the erythrocyte membrane. Microb Immunol 2008; 52: 69–77. doi: 10.1111/j.1348-0421.2008.00015.x PMID: 18380804.
9. Urano-Tashiro Y, Yajima A, Takashima E, Takahashi Y, Konishi K. Binding of the *Streptococcus gordonii* DL1 surface protein Hsa to the host cell membrane glycoproteins CD11b, CD43, and CD50. Infect Immun 2008; 76: 4686–4691. doi: 10.1128/iai.00238-08 PMID: 18678668.
10. Urano-Tashiro Y, Yajima A, Takahashi Y, Konishi K. *Streptococcus gordonii* promotes rapid differentiation of monocytes into dendritic cells through interaction with the sialic acid-binding adhesin. Odontology 2012; 100: 144–148. doi: 10.1007/s10266-011-0044-z PMID: 22006240.
11. Herzberg MC. Platelet-streptococcal interactions in endocarditis. Crit Rev Oral Biol Med 1996; 7: 222–236. PMID: 8908979.
12. Yajima A, Takahashi Y, Konishi K. Identification of platelet receptors for the *Streptococcus gordonii* DL1 sialic acid-binding adhesin. Microbiol Immunol 2005; 49: 795–800. PMID: 16113509.
13. Takamatsu D, Bensing BA, Cheng H, Jarvis GA, Siboo IR, Lopez JA, et al. Binding of the *Streptococcus gordonii* DL1 surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibα. Mol Microbiol 2005; 58: 380–392.
14. Plummer C, Wu H, Kerrigan SW, Meade G, Cox D, Ian Douglas CW. A serine-rich glycoprotein of *Streptococcus sanguis* mediates adhesion to platelets via GPIb. Br J Haematol 2005; 129: 101–109. doi: 10.1111/j.1365-2457.2005.05421.x PMID: 15801962.
15. Seo HS, Xiong YQ, Sullam PM. Role of the serine-rich surface glycoprotein Srr1 of *Streptococcus agalactiae* in the pathogenesis of infective endocarditis. PLoS one. 2013; 8: e64204. doi: 10.1371/journal.pone.0064204 PMID: 23717569.
16. Kerrigan SW, Jakubovics NS, Keane C, Maguire P, Wynne K, Jenkinson HF, et al. Role of *Streptococcus gordonii* surface proteins SspA/SspB and Hsa in platelet function. Infect Immun 2007; 75: 5740–5747. doi: 10.1128/iai.00909-07 PMID: 17893126.
17. Petersen HJ, Keane C, Jenkinson HF, Vickerman MM, Jesionowski A, Waterhouse JC, et al. Human platelets recognize a novel surface protein, PadA, on *Streptococcus gordonii* through a unique interaction involving fibrinogen receptor GPIIbIIa. Infect Immun 2010; 78: 413–422. doi: 10.1128/iai.00664-09 PMID: 19884334.
18. Mitchell J, Sullam PM. *Streptococcus mitis* phage-encoded adhesins mediate attachment to α2-8-linked sialic acid residues on platelet membrane gangliosides. Infect Immun 2009; 77: 3485–3490. doi: 10.1128/iai.01573-08 PMID: 19506011.

19. Takahashi Y, Konishi K, Cisar JO, Yoshikawa M. Identification and characterization of hsa, the gene encoding the sialic acid-binding adhesin of *Streptococcus gordonii* DL1. Infect Immun 2002; 70: 1209–1218. PMID: 11854202.

20. Takahashi Y, Ruhl S, Yoon JW, Sandberg AL, Cisar JO. Adhesion of viridans group streptococci to sialic acid-, galactose- and N-acetylgalactosamine-containing receptors. Oral Microbiol Immunol 2002; 17: 257–262. PMID: 12121477.

21. Ruhl S, Sandberg AL, Cisar JO. Salivary receptors for the proline-rich protein-binding and lectin-like adhesins of oral actinomices and streptococci. J Dent Res 2004; 83: 505–510. PMID: 15153461.

22. Bensing BA, Lopez JA, Sullam PM. The *Streptococcus gordonii* surface proteins GspB and Hsa mediate binding to sialylated carbohydrate epitopes on the platelet membrane glycoprotein Ibα. Infect Immun 2004; 72: 6528–6537.

23. Deng L, Bensing BA, Thamadilok S, Yu H, Lau K, Chen X, et al. Oral streptococci utilize a Siglec-like domain of serine-rich repeat adhesins to preferentially target platelet sialoglycans in human blood. PLoS pathogens 2014; 10: e1004540. doi: 10.1371/journal.ppat.1004540 PMID: 25474103.

24. Pyburn TM, Bensing BA, Xiong YQ, Melancon BJ, Tomasiak TM, Ward NJ, et al. A structural model for binding of the serine-rich repeat adhesin GspB to host carbohydrate receptors. PLoS pathogens 2011; 7: e1002112. doi: 10.1371/journal.ppat.1002112 PMID: 21765814.

25. Perry D, Wondrack LM, Kuramitsu HK. Genetic transformation of putative cariogenic properties in *Streptococcus mutans*. Infect Immun 1983; 41: 722–727. PMID: 6223884.

26. NICE CfCPa. Prophylaxis Against Infective Endocarditis: Antimicrobial Prophylaxis Against Infective Endocarditis in Adults and Children Undergoing Interventional Procedures. London: National Institute for Health and Clinical Excellence; 2008 Mar.

27. Werdan K, Dietz S, Loffler B, Niemann S, Bushnaq H, Silber RE, et al. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nat Rev Cardiol 2014; 11: 35–50. doi: 10.1038/nrrcardio.2013.174 PMID: 24247105.

28. Wilson W, Taubert KA, Gewitz M, Lockhart PB, Baddour LM, Levinson M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116: 1736–1754. doi: 10.1161/circulationaha.106.183095 PMID: 17446442.